On Monday, September 10, the Spanish Parliament passed a bill that could one day lead to the country becoming one of the first in the world to regulate medical cannabis. The bill passed with a comfortable majority, with 232 votes in favor and only 25 against, while the previous day the House of Deputies had rejected the bill by a vote of 149 to 55. Despite the healthy majority, the bill still has to be signed by the Queen, who has the last word on the matter, though it is likely that the bill will be signed. If signed, the new law would provide the country with a framework for regulating the growing and distribution of medical cannabis.
After years of debate over whether to regulate medical marijuana at all, in November 2017 the Spanish government decided to move ahead with medical cannabis regulation. The announcement was received with a mixed reaction: some people were thrilled at the possibility of obtaining cannabis for medical use, while others were concerned at how this would impact the drug’s use among recreational consumers.
The use of medical marijuana is legal in the United States, but even though it is legal to possess, transport, and use marijuana, it can still be a difficult thing to lawfully obtain. The trouble with marijuana is that it’s not regulated like many other drugs.
The fate of legalization will largely depend on the socialists in power. In fact, the government of Prime Minister Pedro Sanchez has shown little enthusiasm for the legalization of medical cannabis. On the 13th. On May 1, the Health Committee of the Spanish Chamber of Deputies approved a proposal to create a subcommittee to study other countries’ experiences with medicinal cannabis. The subcommittee’s findings could pave the way for the legalization of medicinal cannabis in Spain. According to a recent opinion poll, around 90% of Spaniards would support such a measure. In Spain, there is currently no program for medical cannabis at the national level. Two cannabis-based drugs, Sativex and Epidiolex, have been approved by the regulator, but only for the treatment of certain conditions; use for other conditions must be approved by a medical tribunal, taking into account regional differences. Moreover, the cost can be prohibitive.Related Tags:
medical plants sluprohibition partnersu.s. cannabis reportprohibition partners oceania reportprohibition partners south africapp intelligence ltd,People also search for,Privacy settings,How Search works,medical plants slu,prohibition partners,u.s. cannabis report,prohibition partners oceania report,prohibition partners south africa,pp intelligence ltd,prohibition holdings,prohibition partners live